How Bad Are AcelRx Pharmaceuticals's Earnings? | Return On Capital Employed


AcelRx Pharmaceuticals ACRX brought in sales totaling $443.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.55%, resulting in a loss of $10.02 million. AcelRx Pharmaceuticals collected $511.00 thousand in revenue during Q1, but reported earnings showed a $9.14 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, AcelRx Pharmaceuticals posted an ROCE of 0.28%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows AcelRx Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For AcelRx Pharmaceuticals, the positive return on capital employed ratio of 0.28% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Analyst Predictions

AcelRx Pharmaceuticals reported Q2 earnings per share at $-0.08/share, which did not meet analyst predictions of $-0.08/share.

Market News and Data brought to you by Benzinga APIs
Posted In: EarningsBZI-ROCE
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!